Unilever (UL) Supported by Expected Volume Growth Recovery

Key Takeaways

• TD Cowen sets $73 price target, reiterates Buy.
• Expected 2% volume growth by 2026.
• Portfolio shift: sold ice cream, added Liquid I.V., Nutrafol.
• Category-led model gives top markets financial accountability.
• Valuation may converge with US household‑care peers.

Summary

Unilever (UL) is flagged as an oversold European stock, prompting TD Cowen to reiterate its Buy rating with a price target of £58 (about $73). The firm expects the market to recognize a rebound in volume growth, projecting a modest 2% increase by 2026 after the company shed its ice‑cream business and added high‑growth brands like Liquid I.V. and Nutrafol. CEO Fernando Fernandez’s shift to a category‑led, financially accountable model across the top 24 markets aims to boost performance. If volume assumptions hold, Unilever’s valuation multiple could narrow toward that of U.S. household‑care peers.

Pulse Analysis

Unilever’s recent positioning as an oversold stock reflects broader skepticism about European consumer‑goods firms, yet the company’s fundamentals suggest a turnaround. TD Cowen’s renewed Buy rating and a $73 price target underscore confidence that the market has undervalued Unilever’s earnings potential. The firm’s emphasis on volume growth—a key driver for fast‑moving consumer goods—signals that analysts expect a rebound once the company’s strategic initiatives bear fruit. Converting the GBP target to dollars highlights the tangible upside for U.S. investors tracking currency‑adjusted valuations.

Strategically, Unilever has reshaped its portfolio to focus on higher‑margin, high‑growth categories. The divestiture of its ice‑cream segment removes a low‑growth line, while acquisitions such as Liquid I.V. and Nutrafol inject exposure to health‑focused, fast‑growing niches. Coupled with a category‑led operating model that places financial responsibility on executives in the top 24 markets, these moves aim to accelerate organic growth and improve cost efficiency. This realignment aligns Unilever with consumer trends favoring wellness and convenience, positioning it to capture incremental market share.

From a valuation perspective, the anticipated 2% volume growth by 2026 could narrow the gap between Unilever’s multiple and that of its U.S. counterparts like Procter & Gamble and Colgate‑Palmolive. A closer multiple suggests that the market may begin to price Unilever on a more comparable earnings basis, potentially unlocking shareholder value. However, investors should monitor execution risk, especially integration of new brands and the ability to sustain volume gains amid competitive pressure. Overall, Unilever’s strategic pivots and modest growth outlook present a compelling case for a re‑rating in the coming years.